Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 358

1.

Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.

Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, Bernstein D, Edelman R, Edwards KM, Greenberg D, Keitel W, Treanor J, Ward JI; APERT Study.

J Infect Dis. 2004 Aug 1;190(3):535-44. Epub 2004 Jul 7.

PMID:
15243929
2.

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group.

Pediatrics. 2001 Nov;108(5):E81.

PMID:
11694665
3.

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, Greenberg DP, Barenkamp S, Bernstein DI, Edelman R; APERT Study Group.

Clin Infect Dis. 2006 Jul 15;43(2):151-7. Epub 2006 Jun 5.

PMID:
16779740
4.

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.

Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME.

Arch Pediatr Adolesc Med. 1994 May;148(5):503-7.

PMID:
8180641
5.

Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults.

Cherry JD, Chang SJ, Klein D, Lee M, Barenkamp S, Bernstein D, Edelman R, Decker MD, Greenberg DP, Keitel W, Treanor J, Ward JI.

Clin Infect Dis. 2004 Dec 1;39(11):1715-8. Epub 2004 Nov 10.

PMID:
15578376
7.

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.

Cherry JD, Gornbein J, Heininger U, Stehr K.

Vaccine. 1998 Dec;16(20):1901-6.

PMID:
9796041
8.

Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.

Trollfors B, Taranger J, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB.

Clin Infect Dis. 1999 Mar;28(3):552-9.

PMID:
10194077
9.

Serologic response and antibody-titer decay in adults with pertussis.

Heininger U, Cherry JD, Stehr K.

Clin Infect Dis. 2004 Feb 15;38(4):591-4. Epub 2004 Jan 29.

PMID:
14765356
10.

Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.

Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SG.

J Pediatr. 1998 Jun;132(6):983-8.

PMID:
9627590
11.

Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.

Littmann M, Hülsse C, Riffelmann M, Wirsing von König CH.

Vaccine. 2008 May 2;26(19):2344-9. doi: 10.1016/j.vaccine.2008.02.065. Epub 2008 Mar 19.

PMID:
18396360
12.

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, Ljungman M, Hallander HO.

Clin Vaccine Immunol. 2010 May;17(5):741-7. doi: 10.1128/CVI.00469-09. Epub 2010 Mar 24.

13.

IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.

Hendrikx LH, Berbers GA, Veenhoven RH, Sanders EA, Buisman AM.

Vaccine. 2009 Nov 5;27(47):6530-6. doi: 10.1016/j.vaccine.2009.08.052. Epub 2009 Sep 1.

PMID:
19729085
15.

Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.

Knuf M, Zepp F, Meyer C, Grzegowski E, Wolter J, Riffelmann M, Wirsing von König CH.

Vaccine. 2006 Mar 15;24(12):2043-8. Epub 2005 Nov 28.

PMID:
16356597
16.

Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.

Hallander HO, Ljungman M, Jahnmatz M, Storsaeter J, Nilsson L, Gustafsson L.

APMIS. 2009 Sep;117(9):660-71. doi: 10.1111/j.1600-0463.2009.02521.x.

PMID:
19703126
17.
18.

Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine.

Dalby T, Petersen JW, Harboe ZB, Krogfelt KA.

J Med Microbiol. 2010 Sep;59(Pt 9):1029-36. doi: 10.1099/jmm.0.020826-0. Epub 2010 May 27.

PMID:
20508003
19.

Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants.

Gonik B, Puder KS, Gonik N, Kruger M.

Infect Dis Obstet Gynecol. 2005 Jun;13(2):59-61.

20.

Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children.

Tran Minh NN, Edelman K, He Q, Viljanen MK, Arvilommi H, Mertsola J.

Vaccine. 1998 Oct;16(17):1604-10.

PMID:
9713935

Supplemental Content

Support Center